<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)</h1>

    <table>
      <tr><th>Ticker</th><td>EYPT</td></tr>
      <tr><th>Float</th><td>73.3 M</td></tr>
      <tr><th>IO</th><td>83.18%</td></tr>
      <tr><th>MC</th><td>909 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>EyePoint, Inc. (NASDAQ: EYPT) announced non-statutory stock option inducement awards granted to six new employees on February 13, 2026. Aggregate options cover 143,000 shares, granted outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). Exercise price is $12.94 per share (closing price on Feb 13, 2026). Options have a ten-year term and vest over four years (25% at the first anniversary, then monthly over three years). Grants were approved by the Compensation Committee. Company background: clinical-stage biopharma with lead candidate DURAVYU (EYP-1901) in Phase 3 testing for wet AMD and planned DME dosing in early 2026.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>Inducement awards intended to recruit and retain new employees (grants approved by Compensation Committee).</li><li>Exercise price set at closing market price on grant date (no immediate in-the-money economic dilution at grant).</li><li>Standard multi-year vesting aligns employee retention with company milestones.</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>Potential future dilution of up to 143,000 common shares if options are exercised.</li><li>Awards were granted outside the existing 2023 Long-Term Incentive Plan, indicating use of additional share authority.</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/247dfc2b-549f-4ece-9b05-3abb6f3f5b99" target="_blank">Original Article</a>
    </div>

    <div class="small">EYPT • TradersLink AI News</div>
  </div>
</body>
</html>